Katada C, Muto M, Momma K, Arima M, Tajiri H, Kanamaru C, Ooyanagi H, Endo H, Michida T, Hasuike N, Oda I, Fujii T, Saito D
Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Endoscopy. 2007 Sep;39(9):779-83. doi: 10.1055/s-2007-966761.
Endoscopic mucosal resection (EMR) is now commonly indicated for esophageal squamous cell carcinoma (ESCC) within the lamina propria mucosa. However, EMR for ESCC that has invaded the muscularis mucosa is controversial because the risk of lymph node metastasis is not negligible. We conducted a multicenter retrospective cohort study to investigate the incidence of lymph node metastasis and survival after EMR for ESCC invading the muscularis mucosa.
A total of 104 patients with 111 lesions invading the muscularis mucosa, were retrospectively studied at eight institutes. No patients exhibited evidence of metastasis of lymph nodes or distant organs prior to EMR. Overall and cause-specific survival rates were calculated from the date of EMR to the date of death or the most recent follow-up visit. Survival curves were plotted according to the Kaplan-Meier method.
In total, 86 patients (82.7%) who did not receive further treatment such as chemotherapy, irradiation therapy, chemoradiotherapy, or esophagectomy after EMR were followed up. Only two patients (1.9%) developed lymph node metastasis after EMR. With a median follow-up period of 43 months (range, 8-134 months), overall and cause-specific survival rates at 5 years after EMR were 79.5% and 95.0%, respectively.
EMR for ESCC that invades the muscularis mucosa has curative potential as a minimally invasive treatment option.
内镜黏膜切除术(EMR)目前常用于固有层黏膜内的食管鳞状细胞癌(ESCC)。然而,对于侵犯黏膜肌层的ESCC进行EMR存在争议,因为淋巴结转移风险不可忽视。我们进行了一项多中心回顾性队列研究,以调查EMR治疗侵犯黏膜肌层的ESCC后淋巴结转移发生率和生存率。
对8家机构的104例有111处侵犯黏膜肌层病变的患者进行回顾性研究。EMR术前无患者出现淋巴结或远处器官转移的证据。从EMR日期至死亡日期或最近一次随访日期计算总生存率和病因特异性生存率。根据Kaplan-Meier方法绘制生存曲线。
共有86例(82.7%)EMR术后未接受化疗、放疗、放化疗或食管切除术等进一步治疗的患者接受了随访。EMR术后仅2例(1.9%)发生淋巴结转移。中位随访期为43个月(范围8 - 134个月),EMR术后5年的总生存率和病因特异性生存率分别为79.5%和95.0%。
对于侵犯黏膜肌层的ESCC,EMR作为一种微创治疗选择具有治愈潜力。